International Scholarly Research Notices

Research Article

Application of a Reliable LC-MS/MS Method for Determination of Rizatriptan in Healthy Subject Samples: Demonstration of Assay Reproducibility by Incurred Sample Reanalysis

Table 5

Salient features of the present method in comparison with reported procedures for determination of rizatriptan.


Sr. number	Detection technique; LLOQ	Extraction technique; plasma volume for processing	Retention time; run time; maximum on-column loading at ULOQ per injection volume	Organic solvent consumption (extraction and chromatography) per sample analysis	Postcolumn infusion study; relative matrix effect results (% CV)	Incurred sample reanalysis results	Reference

1^a	LC-MS/MS; 0.1 ng/mL	SPE; 1000 μL	3.3 min; 4.0 min; 25 ng	~4.5 mL	NA	NA	[9]
2	HPLC; 0.5 ng/mL	LLE; 1000 μL	5.6 min; 10 min; 10.0 ng	~5.0 mL	NA	NA	[11]
3	LC-MS/MS; 0.05 ng/mL	LLE; 100 μL	1.039 min; 2.0 min; 2.0 ng	~2.5 mL	NA	NA	[12]
4	LC-MS/MS; 0.05 ng/mL	LLE; 500 μL	3.73 min; 5.0 min; 6.0 ng	~3.5 mL	NA	NA	[13]
5	LC-MS/MS; 0.1 ng/mL	LLE; 100 μL	0.94 min; 3.0 min; 125 pg	~4.0 mL	NA	NA	[14]
6^b	LC-MS/MS; 0.5 ng/mL	SPE; 1000 μL	5.1 min; 7.0 min; 6.25 ng	~13.0 mL	NA	NA	[15]
7^c	LC-MS/MS; 1.0 ng/mL	SPE; 1000 μL	3.48 min; 5.0 min; 25 ng	~3.0 mL	NA	NA	[16]
8	LC-MS/MS; 0.2 ng/mL	LLE; 300 μL	1.71 min; 3.0 min; 187.5 pg	~5.0 mL	Yes; 0.5 to 4.6% for 8 lots of plasma	% change from 11.8 to −10.2%	PM

^aIn plasma of dogs; ^balong with sumatriptan;^cin human serum along with zolmitriptan, naratriptan, and sumatriptan; LLOQ: lower limit of quantitation; ULOQ: upper limit of quantitation; SPE: solid phase extraction; LLE: liquid-liquid extraction; NA: data not available; PM: present method.